←
NextMed Health11,496 posts
NextMed Health avatar

NextMed Health

@NextMedHealth

NextMed.Health is a cross-disciplinary program & community from across #healthtech & biomedicine reimagining the future of health & biomedicine.

◷ Joined February 2011▧ 1,486 Photos and videos
Daniel Kraft, MD avatar
⟳ NextMed Health retweeted
Daniel Kraft, MD@daniel_kraft·Nov 1

What if your annual physical became a continuous physical? Wearables + AI could turn everyday health data into insights your care team can act on, between visits. An 80-second glimpse from my conversation with Moira Gunn on @BiotechNation 👇

1:20
NextMed Health avatar
NextMed Health@NextMedHealth·Oct 30

NOW: Leaky heart valves, fixed without reopening the chest. FDA just approved Abbott's Amplatzer Paraclose, the first US catheter device built to plug leaks around surgically replaced heart valves. abbott.mediaroom.com/press-r…… NEAR: Brain stimulation that gives feedback in minutes, not months. Mayo Clinic found that deep brain stimulation for hard-to-treat epilepsy changes brain connectivity within 18 minutes. That could become a fast signal for tuning each patient's settings. newsnetwork.mayoclinic.org/d…… NEXT: Genetic "kill switches" that sculpt mini-organs. University of Pittsburgh scientists built self-destruct circuits that remove faulty cells as lab-grown tissue develops, which yielded more mature liver organoids. It's a step toward truer human tissue models and regenerative medicine. path.pitt.edu/news/dr-mo-ebr… @NextMedHealth • NextMed.Health #FutureOfHealth

Post attachment
NextMed Health avatar
NextMed Health@NextMedHealth·Oct 3

NOW / NEAR / NEXT — Oct 3 NOW: First FDA-approved treatment for MCT8 deficiency (Allan-Herndon-Dudley). Emcitate (tiratricol) lowers excess thyroid hormone when the brain’s hormone transporter is broken. fda.gov/news-events/press-an… NEAR: Aging-cell “senolytic” drugs ease fatty-liver scarring. In fibrotic MASH, dasatinib + quercetin improved fibrosis in 47% vs 7% on placebo (phase 2, Nature Metabolism). nature.com/articles/s42255-0… NEXT: Gene editing reawakens embryonic ζ-globin — a path to treat severe α-thalassemia without lifelong transfusion (Nature Genetics). nature.com/articles/s41588-0… @NextMedHealth | NextMed.Health

Post attachment
Daniel Kraft, MD avatar
⟳ NextMed Health retweeted
Daniel Kraft, MD@daniel_kraft·Sep 29

Infections were responsible for approximately 2.3M cancer cases, or about 12% of diagnoses, worldwide in 2024...

One in eight cancers are caused by infections, a new study finds. And there’s an easy way to protect yourself against most of them: get vaccinated. spklr.io/6018EpPma

NextMed Health avatar
NextMed Health@NextMedHealth·Sep 29

NOW / NEAR / NEXT — the future of health & biomedicine, today. NOW: FDA clears Onswik — a once-weekly basal insulin for adults with type 2 diabetes. Daily-level A1C control, far fewer injections. fda.gov/drugs/news-events-hu… NEAR: An AI model reading pathology + clinical data beat the standard 21-gene test at predicting early and late breast cancer recurrence. Next up: trials that could guide treatment choices. ascopost.com/news/september-… NEXT: AI designs solid-state mRNA vaccines that kept full potency after 2+ months at body temperature — a path to fridge-free shots and microneedle patches worldwide. nature.com/articles/s41587-0… #HealthTech #FutureOfHealth

Post attachment
Daniel Kraft, MD avatar
⟳ NextMed Health retweeted
Daniel Kraft, MD@daniel_kraft·Sep 18

Is it over for human doctors? No. Airliners can largely take off, fly, and land themselves. We still put two pilots up front, for judgment, edge cases, and trust. Same in the exam room. My take on Washington's AI-in-medicine bet, on @NewsNation with @jessecordweber

5:25
Daniel Kraft, MD avatar
⟳ NextMed Health retweeted
Daniel Kraft, MD@daniel_kraft·Sep 18

VIPR: Scientists have discovered a powerful gene-targeting system in viruses. Billions of years old, VIPR seems to predate CRISPR, likely the evolutionary ancestor of CRISPR and may be even more effective. From @kenjmloi, @DoudnaJennifer et al nytimes.com/2026/09/17/scien…

Daniel Kraft, MD avatar
⟳ NextMed Health retweeted
Daniel Kraft, MD@daniel_kraft·Sep 15

AI accelerating scientific discovery: An amplifier of human ingenuity. -AI co-scientist: amplifying hypothesis generation, to research assistants to unlock discovery.... where everyone has a 'virtual lab' polymath AI-collaborator at their disposal... to ask bigger questions and move faster to drive & accelerate science and solutions. Yossi Matias, @YMatias who is head of @Google Research on the acceleration of health & biomedicine With @Johnkwerner @imaginationxyz

Post attachment
NextMed Health avatar
NextMed Health@NextMedHealth·Sep 9

NOW · NEAR · NEXT NOW: First drug for Alexander disease. FDA approved Zanvastro (zilganersen) — an RNA medicine that dials down toxic GFAP. fda.gov/news-events/press-an… NEAR: Lonvo-z, Intellia’s in vivo CRISPR for HAE — rolling BLA underway; potential U.S. launch H1 2027 if approved. One shot vs lifelong prophylaxis. ir.intelliatx.com/news-relea… NEXT: Cellular rejuvenation enters humans. Life Bio dosed the first patient with ER-100 (OSK epigenetic reprogramming) for optic neuropathies. lifebiosciences.com/life-bio…

Post attachment
Daniel Kraft, MD avatar
⟳ NextMed Health retweeted
Daniel Kraft, MD@daniel_kraft·Sep 9

Apple Watch Series 12: new Health Sensing System samples HR every 5s all day, densifies HRV ~24×, and pairs with a Health app Longevity tab + Health Age (VO₂ max, sleep, biomarkers). Continuous physiology → continuous prevention. Via @Apple Newsroom apple.com/newsroom/2026/09/a…

NextMed Health avatar
NextMed Health@NextMedHealth·Sep 7

Incredible work by @biogerontology @InSilicoMeds @InsilicoMed et al

My dear friends, I am happy to report the publication of the most important paper in my life to date (we have several great papers coming out but this is very special). Tomorrow, I will present this paper for the first time at the Nature AI Healthcare in Paris and will post a longer post on this story and its broader implications for how to conduct clinical trials. Please read it and comment on it. Many thanks to the great co-authors of the study and everyone who contributed. Many thanks to the many reviewers (friendly and unfriendly) for spending so much time and helping make it better. Link in the comments.

Post attachmentPost attachment
NextMed Health avatar
NextMed Health@NextMedHealth·Sep 7

One shot. Nearly a year. Kylo-11 (siRNA) cut Lp(a) ~95–97% at 48 weeks after a single injection—Lancet / ESC. The “untreatable” genetic CV risk factor is looking treatable, and annual dosing could fix adherence. Cleveland Clinic / The Lancet, Aug 28 newsroom.clevelandclinic.org…

Post attachment